Eikon Therapeutics to Participate in Multiple Investor Conferences in November

Morgan Stanley webcast will feature Eikon's medical chief discussing new data Nov. 3

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile

$EIKN stock is down 12% today. Here's what we see in our data.

Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$1.4m

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald